Payment overview · 2025
General Payments
$1,448.98
64 reported records · 18 companies
Healthcare provider profile · identity verified
Masoud Afshar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · IMPERIAL, CA · NPI 1225287378
Verified facts
What the public records show
CMS Open Payments records show Masoud Afshar, M.D. received $1,448.98 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auryxia, Farxiga, Gemtesa, Jardiance, Kerendia, Lokelma.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Auryxia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.50 | 13.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $178.28 | 12.3% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $170.17 | 11.7% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.37 | 10.7% | 6 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $129.56 | 8.9% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $128.67 | 8.9% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $112.77 | 7.8% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.04 | 6.2% | 4 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $48.52 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.90 | 3.1% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $41.49 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.06 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.80 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.69 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.52 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.06 | 1.4% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.30 | 1.1% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.28 | 1.1% | 9 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,433.70 | 55 |
| Education | $15.28 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $178.28 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $155.37 | 6 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $150.37 | 4 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $129.56 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $128.67 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $118.35 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $112.77 | 5 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $90.04 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.15 | 3 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $48.52 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $43.74 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $41.49 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| OXLUMO Normalized: oxlumo |
Drug | Alnylam Pharmaceuticals Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Auryxia Normalized: auryxia |
Drug | AKEBIA THERAPEUTICS INC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $15.28 | 9 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auryxia auryxia |
2025 | Auryxia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 177 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 228 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 178 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
177 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
178 | 61 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
228 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carvedilol | Carvedilol | 350 | 91 |
| Hydralazine Hcl | Hydralazine Hcl | 305 | 64 |
| Calcitriol | Calcitriol | 302 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 290 | 75 |
| Furosemide | Furosemide | 281 | 69 |
| Allopurinol | Allopurinol | 270 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 68 |
| Bumetanide | Bumetanide | 249 | 59 |
| Sevelamer Carbonate | Sevelamer Carbonate | 230 | 57 |
| Kerendia | Finerenone | 228 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 62 |
| Potassium Chloride | Potassium Chloride | 188 | 50 |
| Tradjenta | Linagliptin | 184 | 43 |
| Lokelma | Sodium Zirconium Cyclosilicate | 178 | 61 |
| Farxiga | Dapagliflozin Propanediol | 177 | 43 |
| Nifedipine Er | Nifedipine | 160 | 39 |
| Torsemide | Torsemide | 151 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 43 |
| Losartan Potassium | Losartan Potassium | 143 | 31 |
| Procrit | Epoetin Alfa | 118 | 35 |
| Gabapentin | Gabapentin | 102 | 35 |
| Veltassa | Patiromer Calcium Sorbitex | 89 | 23 |
| Metolazone | Metolazone | 85 | 32 |
| Velphoro | Sucroferric Oxyhydroxide | 83 | 30 |
| Lisinopril | Lisinopril | 82 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 65 |
| Ozempic | Semaglutide | 67 | 12 |
| Cephalexin | Cephalexin | 65 | 57 |
| Famotidine | Famotidine | 63 | 13 |
| Chlorthalidone | Chlorthalidone | 58 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 57 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 55 | 19 |
| Lactulose | Lactulose | 55 | 20 |
| Minoxidil | Minoxidil | 55 | 15 |
| Potassium Citrate Er | Potassium Citrate | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 14 |
| Midodrine Hcl | Midodrine Hcl | 45 | 21 |
| Omeprazole | Omeprazole | 43 | 12 |
| Cinacalcet Hcl | Cinacalcet Hcl | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | 12 |
| Alprazolam | Alprazolam | 39 | 15 |
| Jardiance | Empagliflozin | 39 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 14 |
| Xphozah | Tenapanor Hcl | 35 | 12 |
| Glipizide | Glipizide | 34 | 11 |
| Linzess | Linaclotide | 34 | 16 |
| Finasteride | Finasteride | 33 | suppressed |
| Eliquis | Apixaban | 32 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 12 |
| Gemtesa | Vibegron | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 18 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 22 | suppressed |
| Prednisone | Prednisone | 22 | 13 |
| Valsartan | Valsartan | 22 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 19 | 17 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Auryxia | Ferric Citrate | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 16 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,448.98 · 64 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, ACTHAR, Auryxia, CREON, FARXIGA, Fabhalta, Filspari, GEMTESA, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, LOKELMA, LUPKYNIS, OXLUMO, PURIFIED CORTROPHIN GEL, SHINGRIX, TARPEYO, TAVNEOS, TEZSPIRE, VOYXACT, Vafseo | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auryxia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error